Assessment of the timing of histologic and molecular testing indicates that testing occurred prior to treatment initiation for most patients with metastatic non—small cell lung cancer.
Anthony Louder, PhD, RPh
Advertisement
Articles by Anthony Louder, PhD, RPh
Advertisement
Latest Updated Articles
- Molecular Testing Patterns in Metastatic Non—Small Cell Lung Cancer
Published: February 3rd 2016 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Dual JAK Inhibition Demonstrates Efficacy in Progressive Nonsegmental Vitiligo
2
Nerandomilast a "No-Brainer" for First-Line Pulmonary Fibrosis Therapy: Justin M. Oldham, MD, PhD, MS
3
FDA Grants Breakthrough Therapy Designation to R-DXd in CDH6-Expressing Ovarian Cancer
4
FDA Approves Guselkumab for Pediatric Plaque Psoriasis, Active Psoriatic Arthritis
5
